Literature DB >> 10985956

Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.

S J Chen1, D J Rader, J Tazelaar, M Kawashiri, G Gao, J M Wilson.   

Abstract

Adeno-associated viral vectors were used to deliver the gene for very-low-density lipoprotein (VLDL) receptor (VLDLR) to liver of a murine model of familial hypercholesterolemia (FH). Infusion of adeno-associated virus-VLDLR into the portal circulation of FH mice resulted in a 40% reduction in serum cholesterol and triglyceride that was stable for the duration of the study (30 weeks). Fractionation of serum lipids revealed a reduction of both VLDL and low-density lipoprotein. Expression of transgene-derived VLDLR was confirmed in livers of recipient animals by Western blot analysis and immunohistochemistry; vector DNA was present at 1 copy/cell. Vector-treated animals had significantly less lipid accumulation in liver and reduced atherosclerosis in the aorta.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985956     DOI: 10.1006/mthe.2000.0122

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  21 in total

Review 1.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

2.  Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.

Authors:  Federico Mingozzi; Jörg Schüttrumpf; Valder R Arruda; Yuhong Liu; Yi-Lin Liu; Katherine A High; Weidong Xiao; Roland W Herzog
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 3.  Liver-directed gene therapy for dyslipidemia and diabetes.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

Review 4.  Noninvasive imaging of cardiac gene expression and its future implications for molecular therapy.

Authors:  Frank M Bengel
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

5.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

6.  Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector.

Authors:  I H Kim; A Józkowicz; P A Piedra; K Oka; L Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

7.  Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.

Authors:  Sadik H Kassim; James M Wilson; Daniel J Rader
Journal:  Clin Lipidol       Date:  2010-06

8.  Identification and functional characterization in vivo of a novel splice variant of LDLR in rhesus macaques.

Authors:  Sadik H Kassim; Luk H Vandenberghe; Ruben Hovhannisyan; James M Wilson; Daniel J Rader
Journal:  Physiol Genomics       Date:  2011-05-31       Impact factor: 3.107

9.  Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.

Authors:  Sadik H Kassim; Hui Li; Luk H Vandenberghe; Christian Hinderer; Peter Bell; Dawn Marchadier; Aisha Wilson; Debra Cromley; Valeska Redon; Hongwei Yu; James M Wilson; Daniel J Rader
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

Review 10.  AAV-mediated gene therapy for atherosclerosis.

Authors:  Michael Lehrke; Corinna Lebherz
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.